Please ensure Javascript is enabled for purposes of website accessibility

Why AnaptysBio Fell by as Much as 10% Today

By Eric Volkman - Feb 23, 2021 at 6:41PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Perhaps no news is bad news for the ambitious biotech.

What happened

On Tuesday, AnaptysBio (ANAB 0.59%) traded down nearly 10% at one point, before recovering to end the day 2.5% higher. There wasn't any direct news driving such sentiments; rather, it seems other factors were at play.

So what

AnaptysBio is a clinical-stage biotech that concentrates on immunology therapies -- currently a hot area of development in the healthcare world.

At the moment, its leading pipeline drug is imsidolimab, which is currently being developed to treat moderate to severe cases of a rare autoimmune disease called generalized palmoplantar pustulosis.

A researcher studying a sample in a petri dish.

Image source: Getty Images.

Investors are awaiting phase 2 clinical trial results for imsidolimab and they are hopeful; preliminary results indicate that it is extremely efficacious, although the study has only eight participants.

So considering that, plus the fact that there have been no updates about the company's other pipeline drugs, the earlier sell-off might be a case of "no news is bad news" for AnaptysBio.

The company has its believers, however. One of the more powerful ones is analyst Anupam Rama from the JPMorganChase unit J.P. Morgan. On Feb. 11, Rama dramatically increased both his recommendation and price target on the stock, on the back of potentially very strong official results from that imsidolimab trial.

Now what

Expectations remain high for AnaptysBio, and much will depend on the imsidolimab data. Regardless of how it shakes out, the company operates in the exciting and high-potential immunology space, and will definitely continue to be a business for all biotech investors to watch. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

AnaptysBio Stock Quote
$20.42 (0.59%) $0.12
JPMorgan Chase & Co. Stock Quote
JPMorgan Chase & Co.
$118.25 (-1.53%) $-1.84

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.